CN108659099A - A kind of MS probe and its application for hypertensin conversion enzyme activity detection - Google Patents
A kind of MS probe and its application for hypertensin conversion enzyme activity detection Download PDFInfo
- Publication number
- CN108659099A CN108659099A CN201810488931.9A CN201810488931A CN108659099A CN 108659099 A CN108659099 A CN 108659099A CN 201810488931 A CN201810488931 A CN 201810488931A CN 108659099 A CN108659099 A CN 108659099A
- Authority
- CN
- China
- Prior art keywords
- probe
- angiotensin converting
- converting enzyme
- polypeptide
- ace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 title claims abstract description 73
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 12
- 108010072661 Angiotensin Amide Proteins 0.000 title claims abstract description 9
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title claims abstract description 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims abstract description 22
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000001819 mass spectrum Methods 0.000 claims abstract description 14
- 150000004885 piperazines Chemical class 0.000 claims abstract description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000001413 amino acids Chemical group 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 9
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 small molecule piperazine compounds Chemical class 0.000 claims abstract description 7
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- XWINCPYLXQTPQV-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1.C1CNCCN1 XWINCPYLXQTPQV-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 230000029087 digestion Effects 0.000 abstract description 8
- 230000004044 response Effects 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 238000007877 drug screening Methods 0.000 abstract description 3
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical group [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 abstract description 2
- 108010092854 aspartyllysine Proteins 0.000 abstract description 2
- CJNCVBHTDXKTMJ-CYDGBPFRSA-N Ser-Asp-Lys-Pro Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O CJNCVBHTDXKTMJ-CYDGBPFRSA-N 0.000 abstract 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 229960000830 captopril Drugs 0.000 description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 239000001573 invertase Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 2
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- NZWDWXSWUQCNMG-GARJFASQSA-N Asp-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)C(=O)O NZWDWXSWUQCNMG-GARJFASQSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 238000000534 ion trap mass spectrometry Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CPYVQXAASIFAMD-KNIFDHDWSA-N (2s)-2-aminobutanedioic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.NCCCC[C@H](N)C(O)=O CPYVQXAASIFAMD-KNIFDHDWSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical group CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UDYXEHXKWCEKMT-FPAZSGHZSA-N N1[C@@H](CCC1)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N1[C@@H](CCC1)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O UDYXEHXKWCEKMT-FPAZSGHZSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- AWMBNXCUMNOLQI-UHFFFAOYSA-N asperazine Natural products O=C1N(C2C(C3=CC=CC=C3N2)(C2)C=3C=4NC=C(CC5C(NC(CC=6C=CC=CC=6)C(=O)N5)=O)C=4C=CC=3)C2C(=O)NC1CC1=CC=CC=C1 AWMBNXCUMNOLQI-UHFFFAOYSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000033476 cardiovascular system development Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a kind of MS probe for hypertensin conversion enzyme activity detection and its applications, belong to drug screening and assessment technique field.The MS probe, including polypeptide that amino acid sequence is Asp Ser Asp Lys Pro and modify piperazine compounds on the aspartic acid of the polypeptide N-terminal.MS probe provided by the invention by the polypeptide A sp Ser Asp Lys Pro of the angiotensin converting enzyme specific recognition small molecule piperazine compounds responded with high mass spectrum by can be formed by connecting, it can not only be by angiotensin converting enzyme specific recognition and digestion, there is high mass spectrum response simultaneously, Mass Spectrometer Method accuracy is high, can the activity of accurate response angiotensin converting enzyme or the inhibitory activity of angiotensin converting enzyme inhibitors, be also very applicable for from the complex systems such as Chinese medicine compound of the screening with angiotensin converting enzyme inhibition activity.
Description
Technical field
The present invention relates to drug screenings and assessment technique field, and in particular to one kind being used for hypertensin conversion enzyme activity
The MS probe of detection and its application.
Background technology
Angiotensin converting enzyme (Angiotensin-Converting Enzyme, ACE) is a kind of film of zinc dependent form
In conjunction with exopeptidase, it is distributed widely in the tissue of mammal.ACE can pass through renin-angiotensin system (Renin-
Angiotensin system, RAS) and kallikrein kinin system (Kallikrein-kinin system, KKS) catalysis
Angiotensin I converting is Angiotensin II, and bradykinin is made to inactivate, and blood pressure is caused to rise.In addition, the two systems are to electricity
Solution matter and isohydria, cardiovascular system development and Remolding of Functions also play important adjustment effect.Therefore, ACE, which has become, controls
Treat the important target spot of the diseases such as hypertension, acute myocardial infarction AMI and heart failure.
Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe, such as captopril, enalapril, Benazepril, as treatment hypertension and heart failure
First-line drug is applied to clinic.However these drugs are used for a long time and are easy to cause the secondary work such as cough, albuminuria, renal failure
With.In recent years, find that the noval chemical compound with ACE inhibitory activity has become drug screening neck from natural products and traditional Chinese medicine
One research hotspot in domain.
The screening of Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe depends on corresponding method for detecting enzymatic activity.Currently, the active detection methods of ACE are main
Including fluorimetry, spectrophotometry, high performance liquid chromatography, enzyme coupling method etc..These methods are required for greatly by multiple
Step carries out sample process, cumbersome and there is a problem of that sensitivity is relatively low.In addition, the testing principle of these methods is substantially all
It is optical detection, is easy to be interfered by background.Natural products complicated component, in the detection wave band of substrate, there may be stronger
It absorbs, therefore the more difficult screening for directly applying to natural products of these methods.
The patent document of Publication No. CN1831529A discloses a kind of quickly to be sieved with high performance liquid chromatography and mass spectrometry
The method for selecting angiotensin converting enzyme inhibitors, using hippuric acid glycylglycine or hippuric acid histidine leucine as substrate, purifying
Rabbit Pulmonary Vascular angiotensin-converting enzyme or people's blank plasma be angiotensin converting enzyme source, in a water bath heating reaction,
Filter membrane or after centrifugation, with high performance liquid chromatography to substrate in angiotensin converting enzyme reaction mixture, product and
After added internal standard is detached, angiotensin converting enzyme catalysis substrate hydrolysis is detected under the negative ion mode of electrospray ionization mass spectrum
The hippuric acid generated.
Peptide fragment chemical derivatization be protein spectrum analysis in commonly use a kind of Sample Pretreatment Technique Used, by peptide fragment amino,
The small molecule label that easily ionizable is introduced on carboxyl or sulfydryl improves the sensitivity of peptide fragment and specificity and expands mass spectrographic detection model
It encloses.The technology provides a kind of new approaches to design the zymolyte of high sensitivity of mass spectrometry.
Invention content
The purpose of the present invention is to provide a kind of MS probes of high mass spectrum response, as zymolyte, by vasotonia
Plain invertase specific recognition detects vasotonia by the amount of probe or digestion products before and after mass spectroscopy endonuclease reaction
The activity of plain invertase.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of MS probe for hypertensin conversion enzyme activity detection, including amino acid sequence are Asp-Ser-
Piperazine compounds of the polypeptide and modification of Asp-Lys-Pro on the aspartic acid of the polypeptide N-terminal.
The present invention MS probe by can by the polypeptide of angiotensin converting enzyme specific recognition and high mass spectrum response
Small molecule is formed by connecting.The amino acid sequence of the polypeptide is：Asparate-serine-aspartic acid-Lys-Pro
The small molecule of (SEQ ID NO.1), high mass spectrum response are the piperazine compounds ,-NH and polypeptide of piperazine compounds
The carboxyl of the aspartic acid of chain N-terminal is condensed.
Amido bond of the angiotensin converting enzyme restriction enzyme site between aspartic acid-lysine.Therefore, mass spectrum of the present invention
The digestion products of probe are piperazine compounds-asparate-serine-aspartic acid and Lys-Pro.Due to piperazine
Class compound is responded with very strong mass spectrum, therefore reacts the front and back probe or digestion products piperazine compounds-by measuring
The amount of asparate-serine-aspartic acid, you can detect the activity of angiotensin converting enzyme.
Preferably, the piperazine compounds are 1- (2- pyrimidine radicals) piperazine, 1- (4- pyridyl groups) piperazines or 1- (1- first
Base -4- pyridyl groups) piperazine.
More preferably, the piperazine compounds are 1- (2- pyrimidine radicals) piperazine.
Shown in the molecular structural formula of the MS probe such as formula (I),
The present invention also provides a kind of preparation methods of the MS probe described in synthesis, including：
(1) using 2-Chlorotrityl Chloride Resin resins as carrier, fmoc-protected amino acid is raw material,
O- benzotriazole-tetramethylurea hexafluorophosphate is condensing agent, and synthetic amino acid array is Asp-Ser-Asp-Lys-Pro's
Polypeptide；
(2) according to the method for step (1), piperazine compounds are connected on the aspartic acid of the polypeptide N-terminal, matter is made
Probe crude product is composed, it is purified that the MS probe is made.
The present invention modifies piperazine compounds using solid-phase synthesis on the aspartic acid of polypeptide chain N-terminal.The asparagus fern of N-terminal
Propylhomoserin farther out from recognition site, piperazine compounds is modified on the site and do not interfere with ACE identifications.In addition, using synthesis in solid state
Method is easy to modify the carboxyl on Asp side chain, and the yield of probe is higher.
Specifically, the preparation method, including：
One, resin swellings
The 2-Chlorotrityl Chloride Resin resins that degree of substitution is 0.4mmol/g are weighed, resin is put into instead
Ying Guanzhong, add methylene chloride (DCM), vibrates 30min；
Two, connect first amino acid
Solvent is leached out, the Fmoc-L-Pro-OH of 3 times of molar excess is added, adds the diisopropyl second of 5 times of moles
Amine (DIEA) is eventually adding dimethylformamide (DMF) dissolving, vibrates 1h, with DMF and DCM alternately cleaning 6 times；
Three, are deprotected
20% Piperidine/DMF solution is added, reacts 5min, removes solvent, 20% Piperidine/DMF solution is added again, reacts
15min is cleaned twice after reaction with DMF, methanol and DMF；
Four, are condensed
O- benzotriazole-tetramethylurea hexafluoro the phosphorus of Fmoc-L-Lys (Boc)-OH and 3 times of mole of 3 times of moles
Hydrochlorate is dissolved with DMF, and reaction tube is added, and 5 times of mole DIEA are added immediately, reacts 60min；After reaction with DMF, methanol and
DMF is cleaned twice；Above step is repeated, is sequentially connected Asp, Ser, Asp and piperazine compounds from right to left, connection is completed
It is washed 4 times with methanol afterwards, drains 10min；
Five, are cut
Prepare cutting liquid (TFA：Water：EDT：TIS=95：2.5：2：0.5) polypeptide, is cut from resin, obtains crude product spy
Needle.
Six .HPLC purified polypeptides
Purify crude product probe with HPLC, solution after purification be lyophilized, -20 DEG C preserve it is for use.
It is a further object to provide the applications of the MS probe.The MS probe, can as zymolyte
By angiotensin converting enzyme specific recognition, digestion is at piperazine compounds-asparate-serine-aspartic acid and relies
Propylhomoserin-proline.Pass through MS probe or digestion products piperazines before and after mass spectrograph or LC-MS instrument measurement endonuclease reaction
The amount for closing object-asparate-serine-aspartic acid characterizes the activity of angiotensin converting enzyme using difference.
Therefore, the present invention provides the MS probes in the kit for preparing detection hypertensin conversion enzyme activity
In application.
The present invention also provides the MS probes in the kit for preparing screening angiotensin converting enzyme inhibitors
In application.
There is MS probe provided by the invention high mass spectrum to respond, and greatly improve the sensitivity of detection, in addition, by
It is to determine in the molecular weight of MS probe and piperazine compounds-asparate-serine-aspartic acid, the detection method
Selectivity and specificity it is very high, being highly suitable for from the complex systems such as Chinese medicine screening, there is angiotensin converting enzyme to inhibit
Active compound.
The present invention also provides the MS probes in the angiotensin converting enzyme inhibition activity of evaluation drug
Using.The angiotensin converting enzyme inhibition activity of different batches same drug is detected using the MS probe of the present invention, in turn
Evaluate the quality of different batches drug.
The advantageous effect that the present invention has：
MS probe provided by the invention is by can be by the polypeptide A sp-Ser- of angiotensin converting enzyme specific recognition
The small molecule piperazine compounds that Asp-Lys-Pro is responded with high mass spectrum are formed by connecting, can not only be by angiotensin converting enzyme
Specific recognition and digestion, while there is high mass spectrum response, Mass Spectrometer Method accuracy is high, being capable of accurate response vasotonia
The activity of plain invertase or the inhibitory activity of angiotensin converting enzyme inhibitors are also very applicable for from complex systems such as Chinese medicines
Middle compound of the screening with angiotensin converting enzyme inhibition activity.
Description of the drawings
Fig. 1 is the HPLC chromatogram of ACE MS probe purity analysis.
Fig. 2 is the HPLC-IT-MS base peak ion flow graphs of ACE MS probe structural identifications, and wherein upper right corner attached drawing is mass spectrum
Result figure.
Fig. 3 is the activity that ACE MS probes measure various concentration ACE.
Fig. 4 is the inhibiting rate that captopril is measured with ACE MS probes.
Specific implementation mode
The present invention is described further below by specific implementation case.
Embodiment 1
The synthesis of ACE MS probes
The structure of ACE probes is 1- (2- pyrimidine radicals) piperazines-aspartic acid-serine-aspartic acid-lysine-
Proline (PP-Asp-Ser-Asp-Lys-Pro), is synthesized by solid-phase synthesis, is mainly included the following steps that：
One, resin swellings
The 2-Chlorotrityl Chloride Resin resins that degree of substitution is 0.4mmol/g are weighed, resin is put into instead
Ying Guanzhong, add methylene chloride (DCM), vibrates 30min.
Two, connect first amino acid
Solvent is leached out, the Fmoc-L-Pro-OH of 3 times of molar excess is added, adds the diisopropyl of 5 times of molar excess
Ethamine (DIEA) is eventually adding a small amount of dimethylformamide (DMF) dissolving, vibrates 1h.With DMF and DCM alternately cleaning 6 times.
Three, are deprotected
20% Piperidine/DMF solution is added, reacts 5min, removes solvent, 20% Piperidine/DMF solution is added again, reacts
15min.It is cleaned twice with DMF, methanol and DMF after reaction.
Four, are condensed
The HBTU of Fmoc-L-Lys (Boc)-OH and 3 times of molar excess of 3 times of molar excess is dissolved with a small amount of DMF, is added
5 times of molar excess DIEA are added in reaction tube immediately, react 60min.It is cleaned twice with DMF, methanol and DMF after reaction.Repeat with
Upper step is sequentially connected Asp, Ser, Asp and 1- (2- pyrimidine radicals) piperazine, is washed 4 times with methanol after the completion of connection from right to left,
Drain 10min.
Five, are cut
Prepare cutting liquid (TFA：Water：EDT：TIS=95：2.5：2：0.5) polypeptide, is cut from resin, obtains crude product spy
Needle.
Six .HPLC purified polypeptides
Purify crude product probe with HPLC, solution after purification be lyophilized, -20 DEG C preserve it is for use.
Embodiment 2
The chemical characterization of ACE MS probes
ACE MS probes are synthesized using method described in embodiment 1, the purity of probe is analyzed with HPLC.Analysis
Condition is：Prompt human relations 1200HPLC chromatographic systems are equipped with variable-wavelenght detector (VWD), Detection wavelength 214nm；Chromatographic column,
Kromasil C18 (4.6mm × 150mm, 5 μm)；Mobile phase is 0.1% trifluoroacetic acid-water (A) and 0.1% trifluoroacetic acid-second
Nitrile (B)；Flow velocity 1.0mL/min；Isocratic elution, 0-25min, 5-70%B；Sample size, 10 μ L.
After ACE MS probes are dissolved with pure water, 10000rpm is centrifuged 5 minutes, sample introduction.HPLC chromatogram is as shown in Figure 1.
As can be seen that the ACE MS probe purity of synthesis is very high from figure, relative peak area accounting>95%, it can be used for
Subsequent experiment and research.
In addition, we further confirm the structure of probe with HPLC-MS.Analysis condition is：Agilent
1100HPLC chromatographic systems, series LC Q Deca XPplus ion trap mass spectrometries (HPLC-IT/MS)；ESI ion sources；Cation mould
Formula；Mass-to-charge ratio (m/z), 100-1000；Capillary voltage, 15V；Source voltage, 3kV；350 DEG C of capillary temperature；Sheath gas (N2)
60arb；Assist gas (N2) 20arb；Chromatographic column, Zorbax SB C18 (4.6mm × 100mm, 1.8 μm)；Mobile phase is 0.05%
Formic acid-water (A) and 0.05% formic acid-acetonitrile (B)；Flow velocity 0.4mL/min；Gradient is 0-5min, 1%B；5-40min, 1-
30%B；40-45min, 30-100%B；45-50min, 100%B；Sample size, 5 μ L.
The HPLC-IT/MS chromatograms of ACE MS probes are as shown in Figure 2.It can be seen that quasi-molecular ion peak from mass spectrogram
[M+H]+(m/z 707.4) and double-charge ion [M+2H]2+(m/z354.6).These ions match with the structure of probe,
Also further confirm the structure of probe.
Embodiment 3
Application of the ACE MS probes in ACE Activity determinations
Using pH=8.3, the Tris-HCl of 10mM is as buffer solution.Take the ACE solution of ACE MS probes and various concentration
Each 20 μ L, 160 μ L of buffer solution, are placed in the centrifuge tube of 1.5mL, make the final concentration of 0.13mM of ACE MS probes, the end of ACE
A concentration of 0.005-0.06U/mL is incubated 2h at 37 DEG C.400 μ L methanol are added after reaction and terminate reaction.Solution vortex,
Centrifugation, the HPLC-IT/MS methods described in embodiment 2 are analyzed, and with the ACE MS probe enzymolysis products 1- that is generated after reaction, (2- is phonetic
Piperidinyl) piperazine-aspartic acid-serine-aspartic acid amount reflection ACE activity, the results are shown in Figure 3.
From figure as can be seen that in the concentration range, the ACE mass spectrums generated after the concentration (activity) of ACE and reaction are visited
The peak area of needle enzymolysis product has good linear relationship, i.e. ACE concentration is higher, and the probe being digested is more, digestion products
Peak area is also higher.Therefore, which can be used for the Activity determination of ACE.
Embodiment 4
Application of the ACE MS probes in Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe screening
Using pH=8.3, the Tris-HCl of 10mM is as buffer solution.ACE MS probes and each 20 μ L of ACE solution are taken, no
With the 50 μ L of captopril (Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe) of concentration, 110 μ L of buffer solution are placed in the centrifuge tube of 1.5mL, make ACE MS probes
Final concentration of 0.13mM, the final concentration of 0.06U/mL of ACE, the final concentration of 0.08-327nM of captopril are incubated at 37 DEG C
Educate 2h.400 μ L methanol are added after reaction and terminate reaction.Solution is vortexed, centrifuges, the side HPLC-IT/MS described in embodiment 2
Method is analyzed, and enzyme inhibition rate is calculated with following formula：
ACE inhibiting rates (%)=[1- (Pinhibitor/Pblank)] × 100,
Wherein PinhibitorAnd PblankRespectively ACE MS probes after inhibitor group and control group (without inhibitor) reaction
The peak area of enzymolysis product.
Test results are shown in figure 4.From figure as can be seen that as captopril concentration rises, its inhibiting rate to ACE
Also it gradually increases.This shows the inhibiting effect that ACE probes can preferably reflect inhibitor to ACE, can be used for Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe
Screening.
Embodiment 5
Application of the ACE MS probes in the medicine quality evaluated with ACE inhibiting effect
Red rooted salvia powder each 0.5g of 5 different batches is taken, it is accurately weighed, add methanol-water (volume ratio 8:2) it mixes
Solution 50mL, ultrasonic extraction 30min, is dried with centrifugal concentrator, obtains Salvia root P.E powder, slow with Tris-HCl before experiment
Fliud flushing is configured to sample solution.
Using pH=8.3, the Tris-HCl of 10mM is as buffer solution.ACE MS probes and each 20 μ L of ACE solution are taken, it is red
Joining 50 μ L of sample solution, 110 μ L of buffer solution are placed in the centrifuge tube of 1.5mL, make the final concentration of 0.13mM of ACE MS probes,
The final concentration of 0.06U/mL of ACE, the final concentration of 2mg/mL of Radix Salviae Miltiorrhizae are incubated 2h at 37 DEG C.400 μ L first are added after reaction
Alcohol terminates reaction.Solution is vortexed, centrifuges, and the HPLC-IT/MS methods described in embodiment 2 are analyzed, and calculating enzyme with following formula inhibits
Rate：
ACE inhibiting rates (%)=[1- (Pinhibitor/Pblank)] × 100,
Wherein PinhibitorAnd PblankRespectively ACE mass spectrums are visited after Radix Salviae Miltiorrhizae sample sets and control group (without inhibitor) reaction
The peak area of needle enzymolysis product.
The result shows that the inhibiting rate of 5 batch Radix Salviae Miltiorrhizae ACE is respectively 23%, 29%, 19%, 25%, 24%.This shows
The effect of Radix Salviae Miltiorrhizae has ACE certain inhibiting effect, and ACE also invigorates blood circulation with Radix Salviae Miltiorrhizae matches.It therefore, can be compared with using this method
Reflect the bioactivity of Radix Salviae Miltiorrhizae well, it can also be used to the quality evaluation of Radix Salviae Miltiorrhizae.
The foregoing is merely the specific implementation cases of patent of the present invention, but the technical characteristic of patent of the present invention is not limited to
This, any those skilled in the relevant art in the field of the invention, made by changes or modifications all cover the present invention it is special
Among sharp range.
Sequence table
<110>Zhejiang University
<120>A kind of MS probe and its application for hypertensin conversion enzyme activity detection
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Asp Ser Asp Lys Pro
1 5
Claims (7)
1. a kind of MS probe for hypertensin conversion enzyme activity detection, which is characterized in that be including amino acid sequence
Piperazine compounds of the polypeptide and modification of Asp-Ser-Asp-Lys-Pro on the aspartic acid of the polypeptide N-terminal.
2. MS probe as described in claim 1, which is characterized in that the piperazine compounds are 1- (2- pyrimidine radicals) piperazine
Piperazine, 1- (4- pyridyl groups) piperazines or 1- (1- methyl -4- pyridyl groups) piperazine.
3. MS probe as described in claim 1, which is characterized in that the molecular structural formula of the MS probe such as formula (I) institute
Show,
4. the preparation method of MS probe as described in any one of claims 1-3, which is characterized in that including：
(1) using 2-Chlorotrityl Chloride Resin resins as carrier, fmoc-protected amino acid is raw material, O- benzene
And triazole-tetramethylurea hexafluorophosphate is condensing agent, synthetic amino acid array is the more of Asp-Ser-Asp-Lys-Pro
Peptide；
(2) according to the method for step (1), piperazine compounds are connected on the aspartic acid of the polypeptide N-terminal, mass spectrum is made and visits
Needle crude product, it is purified that the MS probe is made.
5. MS probe as described in any one of claims 1-3 is in the kit for preparing detection hypertensin conversion enzyme activity
In application.
6. MS probe as described in any one of claims 1-3 is in the reagent for preparing screening angiotensin converting enzyme inhibitors
Application in box.
7. MS probe as described in any one of claims 1-3 is in the angiotensin converting enzyme inhibition activity of evaluation drug
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810488931.9A CN108659099B (en) | 2018-05-21 | 2018-05-21 | Mass spectrum probe for detecting activity of angiotensin converting enzyme and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810488931.9A CN108659099B (en) | 2018-05-21 | 2018-05-21 | Mass spectrum probe for detecting activity of angiotensin converting enzyme and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108659099A true CN108659099A (en) | 2018-10-16 |
| CN108659099B CN108659099B (en) | 2021-02-02 |
Family
ID=63776251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810488931.9A Active CN108659099B (en) | 2018-05-21 | 2018-05-21 | Mass spectrum probe for detecting activity of angiotensin converting enzyme and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108659099B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110157735A (en) * | 2019-05-27 | 2019-08-23 | 吉林大学 | A kind of building and application of new angiotensin converting enzyme inhibitors screening model |
| CN110734955A (en) * | 2019-10-14 | 2020-01-31 | 浙江大学 | Application of mass spectrometry probes in SGK1 protein activity detection |
| CN111087444A (en) * | 2019-10-14 | 2020-05-01 | 浙江大学 | Mass spectrum probe for DPP-4 activity detection and preparation method and application thereof |
| CN111087445A (en) * | 2019-10-14 | 2020-05-01 | 浙江大学 | Mass spectrometry probe for ACE2 activity detection and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101363779A (en) * | 2008-06-26 | 2009-02-11 | 复旦大学 | Method for enhancing ionization efficiency of peptide segment |
| CN102277154A (en) * | 2011-04-21 | 2011-12-14 | 山东大学 | Phenyl piperazine small-molecule fluorescent probe of alpha1-adrenergic receptor and application thereof |
| CN102608234A (en) * | 2012-03-30 | 2012-07-25 | 国家海洋局第三海洋研究所 | Detection method of angiotensin converting enzyme (ACE) inhibitory activity of antihypertensive peptide |
-
2018
- 2018-05-21 CN CN201810488931.9A patent/CN108659099B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101363779A (en) * | 2008-06-26 | 2009-02-11 | 复旦大学 | Method for enhancing ionization efficiency of peptide segment |
| CN102277154A (en) * | 2011-04-21 | 2011-12-14 | 山东大学 | Phenyl piperazine small-molecule fluorescent probe of alpha1-adrenergic receptor and application thereof |
| CN102608234A (en) * | 2012-03-30 | 2012-07-25 | 国家海洋局第三海洋研究所 | Detection method of angiotensin converting enzyme (ACE) inhibitory activity of antihypertensive peptide |
Non-Patent Citations (3)
| Title |
|---|
| HAIBO WANG: "A novel aggregation-induced emission based fluorescent probe for an angiotensin converting enzyme (ACE) assay and inhibitor screening", 《CHEM. COMMUN》 * |
| XIAOQIANG QIAO: "Piperazines for peptide carboxyl group derivatization: effect of derivatization reagents and properties of peptides on signal enhancement in matrix-assisted laser desorption/ionization mass spectrometry", 《RAPID COMMUN. MASS SPECTROM》 * |
| YAWEI XU等: "Mass Spectrometry Analysis of Phosphopeptides after Peptide Carboxy Group Derivatization", 《ANALYTICAL CHEMISTRY》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110157735A (en) * | 2019-05-27 | 2019-08-23 | 吉林大学 | A kind of building and application of new angiotensin converting enzyme inhibitors screening model |
| CN110734955A (en) * | 2019-10-14 | 2020-01-31 | 浙江大学 | Application of mass spectrometry probes in SGK1 protein activity detection |
| CN111087444A (en) * | 2019-10-14 | 2020-05-01 | 浙江大学 | Mass spectrum probe for DPP-4 activity detection and preparation method and application thereof |
| CN111087445A (en) * | 2019-10-14 | 2020-05-01 | 浙江大学 | Mass spectrometry probe for ACE2 activity detection and preparation method and application thereof |
| CN111087444B (en) * | 2019-10-14 | 2021-08-24 | 浙江大学 | Mass spectrum probe for DPP-4 activity detection and preparation method and application thereof |
| CN111087445B (en) * | 2019-10-14 | 2021-08-24 | 浙江大学 | Mass spectrometry probe for ACE2 activity detection and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108659099B (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108659099A (en) | A kind of MS probe and its application for hypertensin conversion enzyme activity detection | |
| CN108707184B (en) | Mass spectrum probe for thrombin activity detection and preparation method and application thereof | |
| Liu et al. | Rapid identification of bioactive peptides with antioxidant activity from the enzymatic hydrolysate of Mactra veneriformis by UHPLC–Q-TOF mass spectrometry | |
| Feinberg et al. | Modification of peptides containing glutamic acid by hydrogen fluoride-anisole mixtures.. gamma.-Acylation of anisole or the glutamyl nitrogen | |
| CN103242430B (en) | Angiotensin-converting enzyme inhibitory peptide, and preparation method and application thereof | |
| CN105277712B (en) | A kind of method for identifying the modification of lysine ε amino side chains monomethylation | |
| CN110530999A (en) | A kind of distinguishing method between true and false of caribou horn | |
| CN105218640B (en) | A kind of pupa albumen source Angiotensin-Converting inhibits polypeptide and its preparation method and application | |
| CN103897035A (en) | Polypeptide marker for early diagnosis of diabetes mellitus | |
| CN102816832A (en) | Compound with alpha-glucosaccharase inhibitory activity in mulberry leaf and application of compound | |
| CN109541115A (en) | The high-resolution sequence separation of sialylated sugar chain isomer and accurate quantitative analysis method | |
| CN108948176A (en) | A kind of osteopontin feature peptide and its application | |
| CN105237625B (en) | A kind of pupa albumen source Angiotensin-Converting inhibits polypeptide and its preparation method and application | |
| CN104292306B (en) | A kind of polypeptide A LKG and its application in treatment leukemia medicament | |
| Kaur et al. | Purification and characterization of an anticalcifying protein from the seeds of Trachyspermum ammi (L.) | |
| CN101007841A (en) | Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor | |
| NO974750L (en) | Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use | |
| Zhao et al. | A rapid detection and identification of hemorphins released from bovine hemoglobin enzymatic hydrolysis by use of HPLC coupled with photodiode array detector | |
| CN109239211A (en) | For identifying the blood serum designated object and detection kit of human infection Echinococcus hydatid cyst | |
| Raji et al. | Development of an ESI-MS screening method for evaluating binding affinity between integrin fragments and RGD-based peptides | |
| Inoue et al. | Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography–tandem mass spectrometry | |
| CN111087445B (en) | Mass spectrometry probe for ACE2 activity detection and preparation method and application thereof | |
| CN102643334B (en) | Polypeptide molecule for serum in gastric cancer and application | |
| Winkler et al. | Protein labeling and biotinylation of peptides during spot synthesis using biotin p‐nitrophenyl ester (biotin‐ONp) | |
| CN110734955A (en) | Application of mass spectrometry probes in SGK1 protein activity detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |